Robeco Institutional Asset Management B.V. Sells 42,321 Shares of DaVita Inc. (NYSE:DVA)

Robeco Institutional Asset Management B.V. lessened its holdings in DaVita Inc. (NYSE:DVA) by 84.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,022 shares of the company’s stock after selling 42,321 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in DaVita were worth $840,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the business. Deutsche Bank AG increased its stake in shares of DaVita by 421.8% during the 3rd quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock worth $103,518,000 after purchasing an additional 885,195 shares during the last quarter. Invesco Ltd. raised its stake in shares of DaVita by 21.3% during the 3rd quarter. Invesco Ltd. now owns 1,667,255 shares of the company’s stock valued at $157,606,000 after purchasing an additional 292,767 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in DaVita by 148.8% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 365,701 shares of the company’s stock valued at $34,570,000 after buying an additional 218,693 shares in the last quarter. Northern Trust Corp boosted its position in shares of DaVita by 15.7% in the third quarter. Northern Trust Corp now owns 834,608 shares of the company’s stock valued at $78,895,000 after acquiring an additional 113,508 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in DaVita by 2,178.2% in the 4th quarter. Assenagon Asset Management S.A. now owns 108,624 shares of the company’s stock valued at $11,379,000 after purchasing an additional 103,856 shares during the period. 90.12% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DVA. TheStreet upgraded shares of DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 6th. UBS Group raised their target price on shares of DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Barclays upped their target price on DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a report on Monday, May 6th. Finally, Truist Financial raised their price objective on DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, May 15th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $144.67.

DaVita Stock Down 1.9 %

Shares of DaVita stock opened at $132.25 on Friday. The company has a 50-day simple moving average of $135.23 and a two-hundred day simple moving average of $118.31. DaVita Inc. has a 52-week low of $71.51 and a 52-week high of $145.04. The company has a debt-to-equity ratio of 7.95, a quick ratio of 1.37 and a current ratio of 1.43. The stock has a market capitalization of $11.60 billion, a PE ratio of 15.03, a price-to-earnings-growth ratio of 1.03 and a beta of 1.04.

DaVita (NYSE:DVA) last issued its earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, beating the consensus estimate of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The business had revenue of $3.07 billion for the quarter, compared to the consensus estimate of $3.03 billion. During the same period last year, the business posted $1.58 EPS. The company’s revenue was up 6.9% compared to the same quarter last year. On average, analysts anticipate that DaVita Inc. will post 9.62 EPS for the current fiscal year.

Insider Buying and Selling at DaVita

In related news, CEO Javier Rodriguez sold 67,603 shares of DaVita stock in a transaction on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the sale, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Barbara J. Desoer sold 5,030 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $138.81, for a total value of $698,214.30. Following the transaction, the director now owns 10,954 shares of the company’s stock, valued at $1,520,524.74. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.